# BPC-157 Dosage in Research: Doses, Routes, Half-Life, Oral

> How BPC-157 dosage is expressed in the research literature: per-kg animal-model figures, the routes studied including injection and oral, and the under-30-minute half-life. No human dosing guidance.

Animal-model figures, the routes studied, and the pharmacokinetics — read as research context, never as guidance for use.

## How doses are expressed in BPC-157 research

BPC-157 dosage in the literature is expressed as a figure per unit of body weight in an animal model — not as a human dose, because no validated human dose exists. Rodent studies most commonly report doses around 10 µg/kg and 10 ng/kg, and tendon work has gone as low as 10 pg per rat [2]. The gastric-ulcer cytoprotection study used 400 ng/kg and 800 ng/kg in rats [4]. Human pilot data are minimal and use whole-milligram amounts: a 2-person IV safety pilot infused 10 mg then 20 mg [9], and an interstitial-cystitis pilot used a single 10 mg intravesical dose [11].

These are the figures the studies report, logged for the record. This page does not convert them into a human protocol, does not recommend an amount, frequency or duration, and does not describe how to prepare or administer anything. The numbers describe experiments; they are not instructions.

## BPC-157 half-life and pharmacokinetics

BPC-157 half-life is short. The first formal PK/ADME study (2022, rats and beagle dogs) reported an elimination half-life of under 30 minutes for the prototype peptide, with linear pharmacokinetics across doses [5]. Intramuscular bioavailability was around 14-19% in rats and 45-51% in dogs; the peptide broke down rapidly into small fragments entering normal amino-acid metabolism, with excretion via urine and bile [5].

A sub-30-minute half-life is consistent with the repeated daily dosing used throughout the animal literature, and it is one reason the research record does not describe a single-dose "works immediately" effect. Human pharmacokinetics, beyond the tiny safety pilot, are not established [5][9].

## Routes studied (including injection)

BPC-157 injection routes dominate the animal work. The most common rodent route is intraperitoneal, followed by intramuscular; the PK study characterized intravenous and intramuscular delivery [5]. The gastric-ulcer study compared intramuscular against intragastric and found intramuscular outperformed it [4]. Human pilots used intravenous infusion (the 2-person safety study) [9], intravesical instillation (the interstitial-cystitis pilot) [11], and intra-articular injection (the knee-pain case series).

The spread of routes — intraperitoneal, intramuscular, intragastric, local/intra-lesional, intravenous, intravesical, intra-articular — reflects how broadly the peptide has been probed in models, not an endorsement of any route in people. Each route appears here as a fact about study design.

## Oral and peroral BPC-157 in studies

BPC-157 oral administration is studied, and it traces back to the name. BPC-157 is called a *stable gastric pentadecapeptide* because it is reported to be stable in human gastric juice, which is what underlies interest in oral and peroral delivery [1]. Animal studies do use peroral and intragastric routes and report effects [4].

The honest limit: despite the gastric-stability property, formal human oral pharmacokinetics are not established [1]. Reported gastric-juice stability is a molecular observation, not a demonstration that oral BPC-157 produces a defined, measured effect in people. Storage and reconstitution practices discussed online are research-handling context, not validated clinical protocols.

---

The BPC-157 record projected at depth — the cited preclinical findings held on the near plane, the three human pilots a plane back, and the long-term-safety void left dim at the far edge; no clinic behind the projection and nothing here prescribed or sold.